Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced ...

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

This would make amycretin a more effective than other weight loss drugs like Wegovy, where a trial found that patients lost ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly one-quarter of their body weight in early trials.

Novo Nordisk's experimental drug amycretin shows promising results in early trials, aiding significant weight loss in ...